Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
BioPharma Dive1d
Amgen obesity drug on hold; Regeneron sets first dividend
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
Zacks.com on MSN1d
AMGN's Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold
Amgen AMGN reported fourth-quarter 2024 adjusted earnings of $5.31 per share, which beat the Zacks Consensus Estimate of ...
A spine-zapping implant helped 3 people with a muscle-wasting disease walk better
Three people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...
FiercePharma1d
With recent launches and more to come, Amgen's biosimilar business is trending up
After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
Non-Infectious Macular Edema Treatment Market is Projected to Expand at 6.9% CAGR to US$ 29.6 Billion by 2034 | Fact.MR Report
The adoption of telemedicine and remote monitoring technologies in ophthalmology to accelerate the market growth, says Fact.MR in its new market research report.Rockville, MD, Feb. 03, 2025 (GLOBE ...